# EDGAR Filing Document

**Accession Number:** 0001191070
**File Stem:** 0000950170-23-003259
**Filing Date:** 2023-2
**Character Count:** 10891
**Document Hash:** 3697213698ac8434e2dac39518457397
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-003259.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0000950170-23-003259

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230221

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIONOMICS LIMITED/FI
- **CENTRAL INDEX KEY:** 0001191070
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41157
- **FILM NUMBER:** 23645089

**BUSINESS ADDRESS:**
- **STREET 1:** 200 GREENHILL ROAD
- **CITY:** EASTWOOD SA
- **STATE:** C3
- **ZIP:** 5063
- **BUSINESS PHONE:** 61 8 8150 7400

**MAIL ADDRESS:**
- **STREET 1:** 200 GREENHILL ROAD
- **CITY:** EASTWOOD SA
- **STATE:** C3
- **ZIP:** 5063

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**REPORT OF FOREIGN ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of February, 2023** 

**(Commission File No. 001-41157)** 

------

**BIONOMICS LIMITED**

**(Translation of registrant's name into English)** 

------

**200 Greenhill Road**

**Eastwood SA 5063**

**Tel: +618 8150 7400**

**(Address of registrant's principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

------

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

In regard to a General Meeting held in Australia on February 21, 2023, the Company has lodged the Results of the Meeting with the Australian Securities Exchange (ASX), as required by the laws and regulations of Australia. That document is furnished herewith as Exhibit 99.1 to this report on Form 6-K.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1 | [<u>2023 Results of General Meeting</u>](bnox-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | |
|:---|:---|
| **Bionomics Limited** | **Bionomics Limited** |
| (Registrant) | (Registrant) |
| By: | /s/ Errol De Souza<br>|
| Name: | Errol De Souza, Ph.D. |
| Title: | Non-Executive Chairman |

---

Date: February 21, 2023

------

## Ex-99

**Exhibit 99.1**

![img65882896_0.jpg](img65882896_0.jpg)

**ABN 53 075 582 740**

21 February 2023

ASX Market Announcements ASX Limited

Level 4

Stock Exchange Centre 20 Bridge Street

SYDNEY NSW 2000

Dear Sir/Madam,

**RESULTS OF ANNUAL GENERAL MEETING**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution.

This announcement was authorised for release by the Company Secretary.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Ms Suzanne Irwin Company Secretary

+61 8 8150 7400

CoSec@bionomics.com.au

**About Bionomics Limited**

Bionomics Limited (ASX: BNO, Nasdaq: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au

Bionomics Limited \| 200 Greenhill Road, Eastwood, South Australia, +61 8 8150 7400, ABN: 53 075 582 740

------

**BIONOMICS LIMITED**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**GENERAL MEETING**

**Tuesday, 21 February 2023**

**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Resolution details** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Resolution details** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Instructions given to validly appointed proxies**<br>**(as at proxy close)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Instructions given to validly appointed proxies**<br>**(as at proxy close)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Instructions given to validly appointed proxies**<br>**(as at proxy close)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Instructions given to validly appointed proxies**<br>**(as at proxy close)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Number of votes cast on the poll**<br>**(where applicable)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Number of votes cast on the poll**<br>**(where applicable)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Number of votes cast on the poll**<br>**(where applicable)** | &nbsp;&nbsp;&nbsp;&nbsp;**Resolution**<br>**Result** |
| **Resolution** | &nbsp;&nbsp;&nbsp;**Resolution**<br>**Type** | &nbsp;&nbsp;&nbsp;&nbsp;**For** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Against** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Proxy's**<br>**Discretion** | &nbsp;&nbsp;&nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;&nbsp;&nbsp;**For** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Against** | &nbsp;&nbsp;&nbsp;&nbsp;**Abstain\*** | &nbsp;&nbsp;&nbsp;&nbsp;**Carried /**<br>**Not Carried** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Issue of Options to Dr Papapetropoulos | &nbsp;&nbsp;&nbsp;Ordinary | &nbsp;&nbsp;&nbsp;&nbsp;319,929,841<br>90.50% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32,120,106<br>9.09% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,452,010<br>0.41% | &nbsp;&nbsp;&nbsp;&nbsp;427437<br>- | &nbsp;&nbsp;&nbsp;&nbsp;321,381,851<br>90.91% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32,120,106<br>9.09% | &nbsp;&nbsp;&nbsp;&nbsp;427437<br>- | &nbsp;&nbsp;&nbsp;&nbsp;Carried |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Issue of Options to Dr De Souza  | &nbsp;&nbsp;&nbsp;Ordinary | &nbsp;&nbsp;&nbsp;&nbsp;318,690,124<br>90.23% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33,050,348<br>9.36% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,452,010<br>0.41% | &nbsp;&nbsp;&nbsp;&nbsp;736912<br>- | &nbsp;&nbsp;&nbsp;&nbsp;320,142,134<br>90.64% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33,050,348<br>9.36% | &nbsp;&nbsp;&nbsp;&nbsp;736912<br>- | &nbsp;&nbsp;&nbsp;&nbsp;Carried |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Termination Benefits to Dr Papapetropoulos | &nbsp;&nbsp;&nbsp;Ordinary | &nbsp;&nbsp;&nbsp;&nbsp;322,245,358<br>91.22% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29,708,110<br>8.41% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,331,032<br>0.37% | &nbsp;&nbsp;&nbsp;&nbsp;644894<br>- | &nbsp;&nbsp;&nbsp;&nbsp;323,576,390<br>91.59% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29,708,110<br>8.41% | &nbsp;&nbsp;&nbsp;&nbsp;644894 | &nbsp;&nbsp;&nbsp;&nbsp;Carried |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Ratify prior issue of 115,384,680 shares | &nbsp;&nbsp;&nbsp;Ordinary | &nbsp;&nbsp;&nbsp;&nbsp;189,779,948<br>96.75% | 2,002,072<br>1.02% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4,370,829<br>2.23% | &nbsp;&nbsp;&nbsp;&nbsp;157776545<br>- | &nbsp;&nbsp;&nbsp;&nbsp;194,150,777<br>98.98% | 2,002,072<br>1.02% | &nbsp;&nbsp;&nbsp;&nbsp;157776545 | &nbsp;&nbsp;&nbsp;&nbsp;Carried |
| &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. | &nbsp;&nbsp;&nbsp;&nbsp;'\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |

---

------